Reuben Harwood is a Senior Director Analyst with Gartner's Innovation and Emerging Technologies Leadership team, with a focus on the life sciences. Reuben works with technology and business leaders to respond to rapid innovation at the intersection of science and technology. His research explores the rise generative and agentic AI and accelerated use of AI more broadly, to advance drug and scientific discovery. Reuben leads Gartner's coverage of AI drug discovery (AIDD), R&D transformation, genomics/omics, cell and gene therapies and precision medicine. Reuben's work equips life science and healthcare leaders to accelerate AI-driven breakthroughs, turning complex data and workflow challenges into competitive advantage.
Reuben is a Ph.D.-level scientist with a doctorate in cancer research in precision medicine. He has supported C-level leaders and technology executives for over 10 years across various roles. Prior to Gartner, he worked in the life sciences fields of bioinformatics, molecular and cellular biology for leading organizations in the UK and Singapore.
Gartner, Senior Principal, Research, 7 years
Agency for Science, Technology and Research, Senior Research Scientist, 2 years
Life Sciences Industry Technology Insights
Health Ecosystem Technology Insights
Doctor of Philosophy (Ph.D.), Cancer Immunology and Genetics, University of Sheffield, UK
Enabling AI drug discovery, development and in silico research
Using genomics and multiomics data
Unlocking precision medicine
Developing cell and gene therapy (CGT) platforms
Exploring synthetic biology techniques